Experts discuss how the integration of continuous glucose monitoring (CGM) data into electronic health record (EHR) systems enhances clinical decision-making and care coordination, how primary care ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

SiBionics announced today that it unveiled its GS3 continuous glucose monitor (CGM), which now has CE mark approval.

A real-world analysis showed a link between continuous glucose monitor (CGM) distribution channel and outcomes for patients with diabetes.

CGMs are transforming health tracking for non-diabetics, providing insights into glucose levels and influencing dietary choices and athletic performance.

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”). Omnipod 5 ...